Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines
- PMID: 20408848
- DOI: 10.1111/j.1365-2141.2010.08160.x
Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines
Abstract
A joint working group established by the Haemato-oncology subgroup of the British Committee for Standards in Haematology (BCSH) and the British Transplantation Society (BTS) has reviewed the available literature and made recommendations for the diagnosis and management of post-transplant lymphoproliferative disorder in adult recipients of solid organ transplants. This review details the therapeutic options recommended including reduction in immunosuppression (RIS), transplant organ resection, radiotherapy and chemotherapy. Effective therapy should be instituted before progressive disease results in declining performance status and multi-organ dysfunction. The goal of treatment should be a durable complete remission with retention of transplanted organ function with minimal toxicity.
Similar articles
-
Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines.Br J Haematol. 2010 Jun;149(5):675-92. doi: 10.1111/j.1365-2141.2010.08161.x. Epub 2010 Apr 16. Br J Haematol. 2010. PMID: 20408847 Review.
-
Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.Transpl Int. 2006 Apr;19(4):259-69. doi: 10.1111/j.1432-2277.2006.00284.x. Transpl Int. 2006. PMID: 16573540 Review.
-
Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study.Am J Hematol. 2007 Mar;82(3):208-14. doi: 10.1002/ajh.20795. Am J Hematol. 2007. PMID: 17022049
-
Posttransplant lymphoproliferative disorder.Ann Pharmacother. 2007 Nov;41(11):1850-8. doi: 10.1345/aph.1G706. Epub 2007 Oct 16. Ann Pharmacother. 2007. PMID: 17940127 Review.
-
Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.Ann Pharmacother. 2007 Oct;41(10):1648-59. doi: 10.1345/aph.1K175. Epub 2007 Sep 11. Ann Pharmacother. 2007. PMID: 17848421 Review.
Cited by
-
Age and Epstein-Barr viral load at diagnosis of post-transplant lymphoproliferative disease are associated with patient survival in kidney transplant recipients.J Bras Nefrol. 2024 Oct-Dec;46(4):e20240040. doi: 10.1590/2175-8239-JBN-2024-0040en. J Bras Nefrol. 2024. PMID: 39284027 Free PMC article.
-
Late Posttransplant Lymphoproliferative Disease: Report of a Rare Case and Role of Positron Emission Tomography-computed Tomography.Indian J Nephrol. 2018 Sep-Oct;28(5):393-396. doi: 10.4103/ijn.IJN_262_17. Indian J Nephrol. 2018. PMID: 30271004 Free PMC article.
-
Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management.Transplant Direct. 2015 Dec 15;2(1):e48. doi: 10.1097/TXD.0000000000000557. eCollection 2016 Jan. Transplant Direct. 2015. PMID: 27500242 Free PMC article.
-
Management of post-transplant lymphoproliferative disorders.Hemasphere. 2019 Jun 30;3(Suppl):74-77. doi: 10.1097/HS9.0000000000000226. eCollection 2019 Jun. Hemasphere. 2019. PMID: 35309814 Free PMC article. No abstract available.
-
A review of the risks of long-term consequences associated with components of the CHOP chemotherapy regimen.J Drug Assess. 2022 Jun 3;11(1):1-11. doi: 10.1080/21556660.2022.2073101. eCollection 2022. J Drug Assess. 2022. PMID: 35693477 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical